N/A N=50 Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks
Abortion
Primary: Time for Completion of Procedure — 8.0; 9.87 Minutes — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=722 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Subjects in Complete Remission at Month 12 of Maintenance Phase — 47.8; 26.0 percentage of subjects — p=<0.001
Phase 3 N=1,326 A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis, Relapsing-Remitting
Primary: Annualized Qualifying Relapse Rate — 0.15; 0.14; 0.33 relapses per year — p=<0.001
Phase 3 N=867 CLARITY Extension Study
Relapsing-Remitting Multiple Sclerosis
Primary: Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity…
Phase 2 N=15 Fractional Resurfacing Device for Treatment of Acne Scarring
Acne · Scar
Primary: Overall Improvement of Acne Scarring — 2.26; 1.91 units on a scale
N/A N=825 Shared Decision-Making for Colorectal Cancer Screening
Colorectal Cancer
Primary: Patient Adherence (Test Completion) — 104; 116; 96 participants — p=0.046
Phase 3 N=299 A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
Encephalitis · Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis Seroconversion After Vaccination With One Dose of Either Japanese Encephalitis Chimeric Vaccine (JE-CV) or Japanese…
Phase 1 N=99 A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1) — 0; 0; 1 Participants
N/A N=31 A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
Phase 2 N=9 Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer
Pancreatic Neoplasms
Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants
N/A N=365 Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
GARDASIL Vaccination
Primary: On-time Completion of the Human Papillomavirus Vaccine Series — 36; 31 participants
N/A N=18 A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients
Pain
Primary: Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals Across the Whole Brain
Phase 3 N=36 Augmenting Language Therapy for Aphasia: Levodopa
Nonfluent Aphasia · Stroke
Primary: Language Quotient (LQ) on the Western Aphasia Battery — 3.16; 2.59 units on a scale
Phase 2 N=11 Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
Graft-versus-Host Disease
Primary: Response to Bortezomib (VELCADE®) — 2; 2; 4 participants
N/A N=82 Effects of Vibration Training on Exercise Capacity in COPD-patients
Chronic Obstructive Pulmonary Disease
Primary: 6-Minute-Walking-Distance — 64; 37 m